• June 16-19, 2025
  • Boston Convention & Exhibition Center

Sessions

Loading

Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation

Tuesday, June 04, 2024
Breakout Session
Brain Health
26A
A recent study in The Lancet Psychiatry forecasts that half of the global population will experience a mental health disorder in their lifetime. Yet current treatments fall short for up to one third of patients, with treatment resistant major depressive disorder, schizophrenia, and generalized anxiety disorder, among others. To address these failures, there are two paths ahead for innovation: design better drugs for established targets or test entirely new biological mechanisms. Join our panel of experts, each with a unique approach to novel drug development for brain disorders, as they explore the current landscape of innovation in neuropsychiatric drugs and debate where to best direct new efforts. This discussion holds increasing significance within the context of a global mental health treatment market that is expected to exceed $500 billion by 2028.
Moderator
Heather McKenzie
Senior Editor
BioSpace
Speakers
Laxminarayan Bhat, PhD
CEO
Reviva Pharmaceuticals Inc
Amit Etkin, MD
Founder and Chief Executive Officer
Alto Neuroscience
Daniel Karlin, MD
Chief Medical Officer
Mind Medicine (MindMed)
David Benshoof Klein, Co-Founder and CEO
Co-Founder and CEO
Click Therapeutics
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS